236 related articles for article (PubMed ID: 8962317)
1. Cyclosporine neoral monitoring and its correlation with the "area under the curve".
Sabbatiello R; Sgrosso JL; Schiavelli R; Castro C; Ahualli L; Pattin M; Vazquez MC
Transplant Proc; 1996 Dec; 28(6):3378. PubMed ID: 8962317
[No Abstract] [Full Text] [Related]
2. Neoral C2 monitoring in solid organ transplantation.
Levy GA
Transplant Proc; 2004 Mar; 36(2 Suppl):392S-395S. PubMed ID: 15041373
[No Abstract] [Full Text] [Related]
3. Pharmacokinetics of oral cyclosporine (Neoral) in heart transplant recipients during the immediate period after surgery.
Banner NR; David OJ; Leaver N; Davis J; Breen J; Johnston A; Yacoub MH
Transpl Int; 2002 Dec; 15(12):649-54. PubMed ID: 12478413
[TBL] [Abstract][Full Text] [Related]
4. Cyclosporine neoral pharmacokinetics in kidney and heart transplant patients.
Schiavelli R; Sgrosso JL; Sabbatiello R; Castro C; Ahualli L; Pattin M; Vazquez MC
Transplant Proc; 1996 Dec; 28(6):3343-4. PubMed ID: 8962299
[No Abstract] [Full Text] [Related]
5. Evolution of the therapeutic drug monitoring of cyclosporine.
Citterio F
Transplant Proc; 2004 Mar; 36(2 Suppl):420S-425S. PubMed ID: 15041378
[TBL] [Abstract][Full Text] [Related]
6. A limited sampling strategy for the estimation of 12-hour cyclosporine neoral area under the curve in Chinese cardiac transplant recipients.
Wang CH; Ko WJ; Chou NK; Wang SS
Transplant Proc; 2004 Oct; 36(8):2390-2. PubMed ID: 15561259
[TBL] [Abstract][Full Text] [Related]
7. Experience with conversion from Sandimmun to Neoral cyclosporine and the correlation of C2 levels with renal function.
Konstadinidou I; Boletis JN
Transplant Proc; 2004 Mar; 36(2 Suppl):163S-166S. PubMed ID: 15041329
[TBL] [Abstract][Full Text] [Related]
8. Limited sampling strategy to estimate exposure to cyclosporine A in renal allograft recipients treated with Sandimmune-Neoral.
Serafinowicz A; Gaciong Z; Baçzkowska T; Rell K; Lao M; Wałaszewski J
Transplant Proc; 1996 Dec; 28(6):3138-9. PubMed ID: 8962216
[No Abstract] [Full Text] [Related]
9. To keep a stable therapeutic level of cyclosporine during the early posttransplant period is important in graft survival.
Ahn MS; Ha J; Yun IJ; Kim S; Lee JS; Kim S; Han JS; Ahn C; Choi Y; Cheong HI; Kim ST; Kim SJ
Transplant Proc; 1996 Jun; 28(3):1316-7. PubMed ID: 8658675
[No Abstract] [Full Text] [Related]
10. The impact of cyclosporine on the development of immunosuppressive therapy: perspective from a transplant nephrologist involved with the development of C2.
Cole E; Deshpande R
Transplant Proc; 2004 Mar; 36(2 Suppl):408S-413S. PubMed ID: 15041376
[TBL] [Abstract][Full Text] [Related]
11. Conversion from cyclosporine to Neoral in pediatric recipients for kidney, liver, and heart transplantation.
Holmberg C; Laine J; Jalanko H; Leijala M; Hoppu K
Transplant Proc; 1996 Aug; 28(4):2262-3. PubMed ID: 8769219
[No Abstract] [Full Text] [Related]
12. Cyclosporine Neoral profiling in Japanese renal transplant recipients.
Aikawa A; Arai K; Tajima E; Kawamura T; Ogiwara H; Sakai K; Mizuiri S; Ohara T; Hasegawa A; Kosugi T; Kusano A; Matsuo K; Obayashi M; Kurokawa M
Transplant Proc; 2001; 33(7-8):3142-5. PubMed ID: 11750350
[No Abstract] [Full Text] [Related]
13. The area under the concentration-time curve versus trough and peak blood level monitoring in renal transplant recipients on cyclosporine.
Halim MA; Nampoory MR; Johny KV; Donia F; Hamid MH; Said T; Nair MP; Mansour M; Al-Muzairai I; Samhan M; Al-Mousawi M
Transplant Proc; 2005 Sep; 37(7):3019-21. PubMed ID: 16213291
[TBL] [Abstract][Full Text] [Related]
14. Two-hour cyclosporine level determination is the appropriate tool to monitor Neoral therapy.
Cantarovich M; Besner JG; Barkun JS; Elstein E; Loertscher R
Clin Transplant; 1998 Jun; 12(3):243-9. PubMed ID: 9642517
[TBL] [Abstract][Full Text] [Related]
15. Validation of sparse sampling strategies to estimate cyclosporine A area under the concentration-time curve using either a specific radioimmunoassay or high-performance liquid chromatography method.
Koristkova B; Grundmann M; Brozmanova H; Perinova I; Safarcik K
Ther Drug Monit; 2010 Oct; 32(5):586-93. PubMed ID: 20683391
[TBL] [Abstract][Full Text] [Related]
16. Convenience of level of cyclosporine-Neoral at time 3 to determine the area under curve in renal transplant.
Rial MC; Frias S; Argento J; Tessler J; Casadei D
Transplant Proc; 1997; 29(1-2):292-3. PubMed ID: 9123001
[No Abstract] [Full Text] [Related]
17. Conventional versus Neoral cyclosporine in renal transplantation.
Rovelli E; Bucci A; Maldifassi P; Belfiore A; D'Amico G
Transplant Proc; 1998 Aug; 30(5):1764-5. PubMed ID: 9723272
[No Abstract] [Full Text] [Related]
18. Estimated area-under-the-curve monitoring of Neoral in a stable pediatric renal transplant population: one-year experience.
Lemire J; Capparelli EV; MacDonald D; Benador N; Reznik VM; Mendoza SA; Griswold WR
Transplant Proc; 1998 Aug; 30(5):1983-4. PubMed ID: 9723361
[No Abstract] [Full Text] [Related]
19. Neoral conversion study: shift from Sandimmune classic formulation to Neoral in heart and lung transplant patients.
Svendsen UG; Larsen KR; Allermand H; Thayssen P; Jensen SB; Pettersson G
Transplant Proc; 1996 Aug; 28(4):2281. PubMed ID: 8769225
[No Abstract] [Full Text] [Related]
20. The relative importance of cyclosporine exposure in heart, kidney or liver transplant recipients on maintenance therapy.
Hesselink DA; van Dam T; Metselaar HJ; Balk AH; Mathôt RA; Smak Gregoor PJ; Weimar W; van Gelder T
Transpl Int; 2004 Oct; 17(9):495-504. PubMed ID: 15338117
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
